#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Small for dates baby Adenoid cystic carcinoma Asthma Medulloblastoma recurrent Immunodeficiency common variable Raynaud's phenomenon Autoimmune hepatitis Metastatic gastric cancer Spinal cord injury cervical Pemphigoid Autoimmune myositis Haematological malignancy Spinal cord injury Cervix carcinoma Krabbe's disease More trials…

    Learn about Rare Diseases

    Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome – Treatment Noonan syndrome – Basic Information Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome – Basic Information Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome Osteosarcoma Medulloblastoma – Diagnostics Hereditary angioedema – Treatment Familial haemophagocytic lymphohistiocytosis – Trials in Disease Retinitis pigmentosa Osteosarcoma recurrent – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Crovalimab Hdp-101 Acetazolamide AZD0292 Amcenestrant Norfloxacin Vobramitamab Duocarmazine Elamipretide Trihydrochloride Ecoo2 Gemcitabine Dextromethadone Hydrochloride Sarilumab Ascorbic Acid Bp Amlitelimab Ngm707 Betula Verrucosa (108) Xevinapant Vonafexor [14C]ZIPALERTINIB Aspergillus Fumigatus More therapies…

    Learn about Your Condition

    Dent's disease Chondrosarcoma metastatic Large cell lung cancer stage 0 Macular oedema Pancoast's tumour Diabetic autonomic neuropathy Ankylosing spondylitis Hypersensitivity Coronary artery disease Prolymphocytic leukaemia Cirrhosis alcoholic Primary amyloidosis Prostatitis Escherichia coli Vascular malformation Round cell liposarcoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Laiko General Hospital Of Athens

Laiko General Hospital Of Athens

Messogion Avenue 154, Athens, 115 27, Greece

Want to learn more about this study or check if you can participate? Contact us.

  • A Phase 2a Study Evaluating the Efficacy and Safety of MK-8690 in Adults with Moderately to Severely Active Ulcerative Colitis

    Recruiting

    2 1
    France Germany Greece Italy The Netherlands Poland

  • Phase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Nemolizumab
    Bulgaria Croatia France Greece Italy Poland +1

  • A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

    Recruiting

    3 1
    Investigated Drugs:
    • Mrna-4157
    • Pembrolizumab
    France Germany Greece Hungary Italy The Netherlands +2

  • Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

    Recruiting

    2 1
    Investigated Drugs:
    • SPY002
    Austria Belgium Bulgaria Croatia Czechia France +9

  • Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Durvalumab
    • Mk-1084
    France Germany Greece Italy The Netherlands Poland +1

  • Study of MK-1045 versus blinatumomab with tocilizumab in patients with relapsed or refractory B-cell acute lymphoblastic leukemia

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • B-cell type acute leukaemia
    Investigated Drugs:
    • Blinatumomab
    • Tocilizumab
    Denmark France Greece Italy The Netherlands Spain +1

  • Rifabutin plus drug combination for adult patients with hospital‑acquired and ventilator‑associated pneumonia caused by carbapenem‑resistant Acinetobacter baumannii

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Rifabutin
    • SULBACTAM SODIUM
    • Ampicillin Sodium
    Croatia Greece

  • Study of MK-1045 plus rituximab in patients with newly diagnosed follicular lymphoma

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Follicular lymphoma
    Investigated Drugs:
    • Vinorelbine
    • Bendamustine Hydrochloride
    • Betamethasone Sodium Phosphate
    France Germany Greece Italy Poland Spain

  • Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Small cell lung cancer
    Investigated Drugs:
    • Topotecan Hydrochloride
    Austria Belgium Czechia Denmark France Germany +5

  • Study of PF-07275315 versus placebo for efficacy and safety in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD)

    Recruiting

    2 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Bulgaria Czechia France Germany Greece Hungary +3
Previous Page
1 2 3 4 … 38
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!